Dr. Michelle Papka: On Emerging Non-Invasive Alzheimer’s Treatments

This Live Talk is produced by Being Patient with support provided by Cognito Therapeutics. 

Researchers and technology companies are looking into whether non-invasive electromagnetic, visual, and auditory stimulation can treat Alzheimer’s disease. But what do we know now about these emerging non-drug interventions and what they can do for the brain?

On Friday, February 7th, at 10 a.m. PT/1 p.m. ET, Dr. Michelle Papka, Founder and President of the Cognitive and Research Center of New Jersey (CRCNJ), will join Being Patient Live Talks to discuss emerging technology-assisted noninvasive interventions for Alzheimer’s disease. These include treatments like the SPECTRIS AD, which causes gamma wave activity with noninvasive visual and auditory stimulation. 

Papka, a neuropsychologist, psychotherapist, and researcher, has over 30 years of combined experience specializing in aging, Alzheimer’s disease, and dementia. For over 15 years, she has also served as the Principal Investigator on industry-sponsored clinical trials for Alzheimer’s disease and age-related cognitive impairment. She is an active public speaker, invited editor, grant reviewer, consultant, and committee member of multiple specialized organizations and publications in aging and Alzheimer’s Disease. Papka is also the author and creator of “Memory Matters,” a monthly Q & A column about cognitive aging published in the NJ Star Ledger.

After working as a neuropsychologist in academia, Papka founded her private clinical practice in 2001 and the CRCNJ in 2009. She presides over the flagship site in Springfield, NJ, and the newer site in Ridgewood, NJ. Pinnacle Clinical Research recently acquired the CRCNJ. Papka is now the scientific director of CNS for the Pinnacle Network and a Key Opinion Leader Consultant to CNS at Summit Clinical Research, a related entity.

RSVP to the live talk to learn her perspective on non-invasive interventions for Alzheimer’s disease and what the future may hold for these treatments.